- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05682911
Protective Effect of Zingiber Officinale L. Extract in Hypertensive Patients
Hypolipidemic, Cardioprotective and Antioxidant Effect of Zingiber Officinale L. Extract in Hypertensive Patients: A Clinical Approach
Study Overview
Status
Intervention / Treatment
Detailed Description
- Study area and setting The study covered the period of January, 2018 to June, 2018 in the Al-Khidmat Medical and Diagnostic Center Nazimabad No.2, Karachi. This was carried out with the cooperation of Cardiac OPD and Laboratory Department of Al-Khidmat Medical and Diagnostic Center. All procedures were approved by the Independent Ethics Committee (IEC) of International Center for Chemical and Biological Sciences (ICCBS), University of Karachi (Study Number. 026-HV/HP-2017, Protocol Number. ICCBS/IEC-026-HV/HP-2017/Protocol/2.0) dated December 08, 2017.
- Study design This was single blind randomized clinical Study of 40 hyperlipidemic patients. The determination of sample size was done on basis of data from past studies and calculated from formula on SPSS. All the newly diagnosed hyperlipidemic patients were recruited according to the inclusion and exclusion criteria. the written informed consent in local language was being taken to all before the study. The questionnaires used to record information related to the demographic profile, age, gender, family history, past medical history, past laboratory findings, diagnosis and current treatment. All pateints were examined with blood pressure, pulse rate, total lipid profile and cardio-vascular biomarker.
Selection of participants A total 40 newly diagnosed hyperlipidemic patients visiting Cardiac OPD at Al-Khidmat Medical and Diagnostic Center, Nazimabad No. 2 Karachi were selected for this study on basis of inclusion and exclusion criteria. Patients were randomized (1:1) using a computer-generated table into two groups: the control group received simvastatin and treated group powder tablets twice a day. Ginger treated group was treated with ginger powder tablets 500mg twice a day (BD) for two month while Simvastatin treated group was maintained on simvastatin 20 mg tablet once a day (OD) for two month. All the patients were over eighteen years of age, conversant in Urdu, consented to be available for participation in eight week study (Two months). The duration of treatment was decided on basis of previous studies carried.
The inclusion criteria included patients were above 18 years age, either male or female with the diagnosis of hyperlipidemia, total cholesterol up to 200-239mg/dl and LDL 100-159mg/dl. They must not receive lipid-lowering drugs for at least 3 months prior to the recruitment and clinical laboratory tests (CBC, Blood Chemistry, and Urinalysis) were within normal ranges. Exclusions criteria were any cardiovascular diseases, seizures, previous liver surgery, poor controlled diabetes, and drug/alcohol dependence, pregnancy and GI ulcer. Subjects receiving antihyperlipidemic agents (Statins, Niacin, Fibrates and Bile Sequestrants) were excluded in recent past. Blinding was maintained by keeping identical packaging of the ginger and simvastatin drugs with different codes, and no aroma was detected from either; the participants were blinded to the treatment allocation.
- Study protocol Patients that met the above criteria and gave written consent were randomized to the Treatment group (ginger tablet) and the Control group (Simvastatin) for 8 weeks. During the initial evaluations, all patients interviewed by taking patients previous history included the questions about medical illness, medications, allergies and family history of illness and disease status, blood pressure and pulse rate on every visit. Blood sample (5 ml) was taken before and after treatment for total Lipid Profile, SGPT, SGOT, CK-MB and C-RP. Erythrocyte antioxidant enzymes activity of superoxide dismutase (SOD) and glutathione peroxidase (GPX) were determined by spectrometric method using Ransod and Ransel kit, respectively. Upon every visit all patients were also screened with their blood pressures, heart rate, sleep pattern by insomnia severity indexed (26) and memory by MMSE (27). Analysis was blinded and was performed at the same laboratory for all patients. All Adverse effects reported during the study period were monitored using a structured questionnaire. The questionnaire consisted of questions about the occurrence of ADR such as diarrhea, nausea and/or vomiting, abdominal pain, metallic taste, symptoms related to an allergic reaction, headache, dizziness or any other undesirable effect.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Sindh
-
Karachi, Sindh, Pakistan, 75850
- Alkhidmat Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females (18-65)
- Diagnosis of primary hypercholesterolemia
- With total cholesterol 200-239mg/dl and LDL 100-159mg/dl.
Exclusion Criteria:
- Familial hypoalphalipoproteinemia
- Patients receiving antihyperlipidemic agents (Statins, Niacin, Fibrates and Bile Sequestrants) were excluded in recent past.
- Pregnant, breast feeding and women likely to become pregnant
- Subjects excluded who suffered from allergy or hypersensitivity from Ginger or its tablet excipients.
- All those subjects excluded with severe or unstable medical conditions like renal failure, Seizures, previous liver surgery, poor controlled diabetes, and drug/alcohol dependence.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Zingiber Officinale L (Ginger) treated group n=20
Ginger tablets 500mg twice a day (BD) for two month
|
Zingiber officinale L. tablets 500mg twice daily
Other Names:
|
Active Comparator: Simvastatin treated group n=20
Simvastatin 20 mg tablet once a day (OD) for two month
|
Simvastatin 20mg once a day for 2 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of total lipid profile
Time Frame: baseline to 2 month
|
Change in total cholesterol, triglycerides, High Density Lipoprotein (HDL)Low Density Lipoprotein-cholesterol (LDL) at baseline Change from baseline in total cholesterol, triglycerides, High Density Lipoprotein (HDL)Low Density Lipoprotein-cholesterol (LDL) after 2 months |
baseline to 2 month
|
Assessment of cardio protective profile
Time Frame: baseline to 2 month
|
Change from baseline in serum glutamic-oxaloacetic transaminase (SGOT), glutamic-pyruvic transaminase (SGPT).
|
baseline to 2 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the antioxidant effect
Time Frame: baseline to 2 months
|
Change From Baseline in antioxidant markers Superoxide dismutase (SOD), Glutathione peroxidase
|
baseline to 2 months
|
Effect on sleep cycle
Time Frame: baseline to 2 months
|
To evaluate the sleep patterns by using Insomnia Severity Index (ISI) scale after 2 month Total score categories: 0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe) |
baseline to 2 months
|
Effect on C-reactive protein (CRP)
Time Frame: baseline to 2 months
|
Change From Baseline in antioxidant marker C-reactive protein (CRP)
|
baseline to 2 months
|
Effect on memory
Time Frame: baseline to 2 months
|
Change in memory enhancement effect through mini mental state examination (MMSE) scale at baseline and after 2 months The maximum score for the MMSE is 30. A score of 25 or higher is classed as normal. If the score is below 24, the result is usually considered to be memory impairment. |
baseline to 2 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 026-HV/HP-2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on The Main Focus of This Study is to Evaluate the Safety of Zingiber Officinale L. Tablets as Hypolipidemic Agent in Hypertensive Patients
-
Lotus PharmaceuticalUnknownThe Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg | Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in | Subjects With Type 2 Diabetes Mellitus.Taiwan
Clinical Trials on Zingiber officinale L. tablets
-
Shahid Beheshti UniversityCompletedAcute Respiratory Distress SyndromeIran, Islamic Republic of
-
Chonbuk National University HospitalCompleted
-
Azienda di Servizi alla Persona di PaviaCompleted
-
Vedic Lifesciences Pvt. Ltd.Completed
-
Tehran University of Medical SciencesCompleted
-
Joel YarmushCompletedNausea | VomitingUnited States
-
Ain Shams UniversityCompleted
-
Allama Iqbal Open University IslamabadCompletedPulmonary Tuberculosis | Gastro-Intestinal DisorderPakistan
-
AngiogenixUnknownSickle Cell DiseaseUnited States